CSPC Pharmaceutical GroupCSPCY +9.11%74 Buyback Yield % is 0.48 as of Jul. 07, 2026, which is 500% above its 10-year median of 0.08. GuruFocus rates CSPCY with a GF Score™ of 74/100 and a GF Value™ of $3.36 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 78.35% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPCY vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (CSPCY) has a Buyback Yield % of 0.48 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CSPC Pharmaceutical Group and its competitors. This is 500% above median its historical median of 0.08. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #63 out of 291 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is CSPC Pharmaceutical Group's Buyback Yield % too high?
CSPC Pharmaceutical Group's current Buyback Yield % of 0.48 is 500% above median its 10-year median of 0.08. Based on the distribution chart, CSPC Pharmaceutical Group ranks #63 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CSPC Pharmaceutical Group has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #63 out of 291 companies for Buyback Yield %. This places CSPC Pharmaceutical Group in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Buyback Yield % is 0.48, which is 500% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.19 — trading 24.7% above its estimated fair value. The current Buyback Yield % is 0.48, which is 500% above median its 10-year median of 0.08. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Buyback Yield % is 0.48 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $4.19 is trading 24.7% above its estimated GF Value™ of $3.36.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
Buyback Yield %: 0.48 (500% above median its 10-year median of 0.08)
GF Value™: $3.36 vs. price of $4.19 (24.7% above fair value)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score
Get the complete analysis for CSPCY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
